Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

29 Jun 2022

Abstract excerpt

Multiple myeloma is the second most common hematological malignancy. Despite significant advances in treatment, relapse is common and carries a poor prognosis. Thus, it is critical to elucidate the genetic factors contributing to disease progression and drug resistance. Here, we carry out integrative clinical sequencing of 511 relapsed, refractory multiple myeloma (RRMM) patients to define the disease's molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Multiple Myeloma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35768438
DOI: 10.1038/s41467-022-31430-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myelomaPMID 35768438Read ↗

Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistanceSemantic proximity Read ↗

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.Semantic proximity Read ↗

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaSemantic proximity Read ↗

miRNAs driving diagnosis, progression, and drug resistance in multiple myelomaSemantic proximity Read ↗

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic StrategiesSemantic proximity Read ↗

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic markerSemantic proximity Read ↗

Epidemiology, genetics and treatment of multiple myeloma and precursor diseases.Semantic proximity Read ↗

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.Semantic proximity Read ↗

Genetic Subtypes of Smoldering Multiple Myeloma are associated with Distinct Pathogenic Phenotypes and Clinical OutcomesSemantic proximity Read ↗

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.